Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis

OBJECTIVES: Infertility imposes considerable clinical and economic burden, and the high costs of fertility care are a major barrier to payers. This study assessed the cost differences of highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follicle stimulating hormone (rFSH) for...

Descripción completa

Detalles Bibliográficos
Autores principales: Khair, Andrew, Brown, Tray, Markert, Marie, Barsøe, Carsten Rødseth, Daftary, Gaurang S., Heiser, Patrick W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471533/
https://www.ncbi.nlm.nih.gov/pubmed/37480456
http://dx.doi.org/10.1007/s41669-023-00429-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471533/
https://www.ncbi.nlm.nih.gov/pubmed/37480456
http://dx.doi.org/10.1007/s41669-023-00429-8

Ejemplares similares